site stats

Platinum resistant hgsoc

Webb29 nov. 2024 · Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP … Webb6 okt. 2024 · HGSOC is an excellent tumour model of high replication stress (Supplementary Fig. 1 ). Almost all HGSOCs bear TP53 mutations, whereas CCNE1 amplification occurs in 20% of cases, biallelic RB1...

Hyper-phosphorylation of Sequestosome-1 Distinguishes …

Webb3 mars 2014 · Resistance to platinum chemotherapy is one of the main factors driving ovarian cancer mortality, and overcoming platinum resistance is considered one of the … WebbHigh grade serous ovarian cancer (HGSOC) patients have a high recurrence rate after surgery and adjuvant chemotherapy due to inherent or acquired drug resistance. Cell lines derived from HGSOC tumors that are resistant to chemotherapeutic agents represent useful pre-clinical models for drug discover … fridyai https://stampbythelightofthemoon.com

Establishment and characterization of a platinum- and paclitaxel ...

Webb31 mars 2024 · While most HGSOC patients show a good response to the conventional platinum-based chemotherapy, ~ 15% of women experience primary resistance to these treatments [ 20, 21, 22, 23, 24 ]. To date, there are no validated predictive markers of primary platinum refractory or resistant disease. Webb10 aug. 2024 · The major cause of cancer recurrence is resistance to platinum-based agents, that can be “intrinsic” in 10% to 15% of HGSOC patients, defined as platinum-refractory, or developed within 6 months of completing chemotherapy for approximately 20% to 30% of patients, named platinum-resistant [ 5 ]. Webb23 jan. 2024 · High-grade serous ovarian cancer (HGSOC) is currently treated with cytoreductive surgery and platinum-based chemotherapy. The majority of patients show a primary response; however, many rapidly develop drug resistance. Antiestrogens have been studied as low toxic treatment options for HGSOC, with higher response rates in … fat\\u0027s asia bistro roseville

HGSOC-Platinum - Database Commons - CNCB

Category:Development of a Genomic Signatures-Based Predictor of Initial Platinum …

Tags:Platinum resistant hgsoc

Platinum resistant hgsoc

Multiomic analysis identifies CPT1A as a potential therapeutic …

Webb15 sep. 2024 · In addition, higher HSD17B14 and CYP1A2 expressions were observed in highly chemoresistant COV362 cells and platinum-resistant tissues compared to those in HIO-80 cells and platinum-sensitive tissues. The HGSOC cell models differed in HSD17B10, CYP1B1, and NQO1 expression. Webb15 sep. 2024 · Seven copy number signature patterns that predict both overall survival and the probability of platinum-resistant relapse have been described in HGSOC tumours on …

Platinum resistant hgsoc

Did you know?

WebbThe approval was based on an integrated efficacy analysis of 106 platinum-treated patients (both sensitive and resistant) with HGSOC and a BRCA mut participating in study 10 50 and ARIEL2. 5 Rucaparib 600 mg twice daily was associated with a median progression-free survival (PFS) time of 10.0 months (95% CI, 7.3–12.5) and a median … Webb2 nov. 2024 · Meanwhile, we found that the HGSOC patients who harbored heteroplasmic pathogenic mtDNA somatic mutations had significantly higher prevalence of both platinum-resistance and relapse than those without (80.0% versus 16.7%, p=0.035).

Webb3 sep. 2024 · Platinum-resistant tumorspheres can acquire a dependence on FAK for growth. Accordingly, increased FAK tyrosine phosphorylation was observed within HGSOC patient tumors surviving neo-adjuvant chemotherapy. Combining a FAK inhibitor with platinum overcame chemoresistance and triggered cell apoptosis. Webb23 nov. 2024 · HGSOC patients who progress during initial treatment of platinum-based chemotherapy or completely alleviated after initial treatment that includes cytoreductive surgery and the platinum-based chemotherapy but recur within 6 months are defined as platinum-resistant recurrent (PRR) ovarian cancer patients ( 5, 6 ), and platinum …

Webb2 mars 2024 · At present, typical treatment for patients with high-grade serous ovarian cancer (HGSOC) is surgical debulking coupled with platinum-based chemotherapy. … Webb5 mars 2024 · Although platinum-based chemotherapy has been the cornerstone for HGSOC treatment, nearly 25% of patients would have less than 6 months of interval …

WebbPlatinum-resistance is a major limitation to effective chemotherapy regimens in high-grade serous ovarian cancer (HGSOC). To better understand the mechanisms involved we …

Webb5 mars 2024 · Although platinum-based chemotherapy has been the cornerstone for HGSOC treatment, nearly 25% of patients would have less than 6 months of interval since the last platinum chemotherapy,... fat\\u0027s chicken and wafflesWebbDetails about 2024 Canadian Silver Dollar Proof Platinum Jubilee Queen Elizabeth II See original listing. 2024 Canadian Silver Dollar Proof Platinum Jubilee Queen Elizabeth II : Condition:--not specified. Ended: Apr 14, 2024. Starting bid: US $99.95 [ 0 bids] Shipping: FREE Standard ... fat\u0027s chicken and waffles menuWebb图5. 与甲基化brca1等位基因存在相关的hgsoc的风险比情况. 结论：正常组织brca1启动子甲基化与tnbc、hgsoc的发生风险显著相关，对这些癌症的预测具有潜在意义。此发现值得进一步研究，以确定肿瘤抑制基因的体质甲基化是否为泛癌危险因素。 原文链接： fridy manditaWebb3 sep. 2024 · Adhesion-independent FAK signaling sustained KMF and human tumorsphere proliferation as well as resistance to cisplatin cytotoxicity. Platinum-resistant tumorspheres can acquire a dependence on FAK for growth. Accordingly, increased FAK tyrosine phosphorylation was observed within HGSOC patient tumors surviving neo … friearndt.comWebbWe demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance. When these cancer stem cells differentiated into their chemosensitive progeny, they lost tumor-initiating capacity and p53 aggregates. frid water filterWebb4 apr. 2024 · Request PDF Abstract 1562: Correlative biomarker analysis of the phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in BRCA wild-type (BRCAwt), platinum-resistant ... fat\\u0027s chicken and waffles seattleWebbHigh-grade serous ovarian cancer (HGSOC) harbours aberrant epigenetic features, including DNA methylation. In this study we delineate pathways and networks altered by … fat\u0027s folsom ca